NeoGenomics (NGNM.OB) Posts Financial Results for Difficult Q4 and FY2010, Optimistic of Future
NeoGenomics Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter 2010 and fiscal year ended December 31, 2010. Douglas VanOort, chairman and CEO, noted difficult times for the company, as well as positive achievements. "We experienced many headwinds in 2010 that impacted our revenue growth and our profitability. Despite these headwinds, we grew our core revenue faster than many in our laboratory peer group,” VanOort stated in the press release. “In addition, the quality of our service to clients is outstanding and our recent cost cutting initiatives and productivity enhancements are starting…